| |
| Section: |
Injections |
| Number: |
I-5 |
| Topic: |
Chelation Therapy/Chemical Endarterectomy |
| Effective Date: |
August 1, 2005 |
| Issued Date: |
August 1, 2005 |
| Date Last Reviewed: |
07/2005 |
General Policy Guidelines
Indications and Limitations of Coverage
Chelation Therapy
When the Edetate Calcium Disodium (J0600) is reported for chelation therapy for heavy metal poisoning (961.1, 961.2, 964.0, 984, 984.0, 984.1, 984.8, 984.9, 985.1, 985.5, and 985.8) or Wilson's disease (275.1) (hepatolenticular degeneration), is reported, coverage for treatment is determined according to individual or group customer benefits.
Chelation therapy is also eligible for the treatment of the following conditions:
- Control of ventricular arrhythmias or heart block associated with digitalis toxicity
- Emergency treatment of hypercalcemia
- Thalassemia intermedia with hemochromatosis
The agent used for chelation therapy (J0600) should be denied as not covered when used to treat conditions other than those referenced above.
Chemical Endarterectomy
Use of Edetate Disodium (J3520) in the treatment of atherosclerosis, arteriosclerosis, or any other condition is considered experimental/investigational and, therefore, is not covered. These are not FDA approved indications and scientific evidence does not demonstrate that safety and efficacy have been proven. A participating, preferred, or network provider can bill the member for the denied service.
M0300 represents either the intravenous administration of the chelating agent or the intravenous administration of EDTA (J3520).
Description
Chelation Therapy
Chelation therapy is the treatment of choice for heavy metal poisoning. The treatment consists of the intravenous administration (M0300) of chelating agents (e.g., Edetate Calcium Disodium (J0600), Endrate) to promote excretion of the offending metal. Treatment may also include medical care.
Chemical Endarterectomy
Chemical endarterectomy is a form of treatment used for the removal of plaque or calcium. It consists of the intravenous administration (M0300) of Edetate Disodium - EDTA (J3520) for conditions such as atherosclerosis, arterio-sclerosis, or similar generalized conditions. |
- NOTE:
- This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
|
Procedure Codes
Traditional Guidelines
FEP Guidelines
The medical necessity guidelines are applied pre-payment for FEP.
|
PPO Guidelines
Managed Care POS Guidelines
Publications
PRN References
06/1997, Chelation therapy/chemical endarterectomy
10/1997, Chelation therapy/chemical endarterectomy policy will not change
02/1998, Coverage for chemical endarterectomy discontinued |
References
Chelation Therapy for Coronary Heart Disease: An Overview of All Clinical Investigations, American Heart Journal, Vol. 140, No. 1, 07/2000
Chelation Therapy for Ischemic Heart Disease, A Randomized Controlled Trial, Jounal of the American Medical Association, Vol. 287, 01/2002
Edetate Calcium Disodium, USPDI - Vol. I, Edition 21, 2001 Micromedex, Inc. |
View Previous Versions
No Previous Versions
Table Attachment
Text Attachment
Procedure Code Attachment
Glossary
 |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Medical policies are designed to supplement the terms of a member's contract. The member's contract defines the benefits available; therefore, medical policies should not be construed as overriding specific contract language. In the event of conflict, the contract shall govern.
Medical policies do not constitute medical advice, nor the practice of medicine. Rather, such policies are intended only to establish general guidelines for coverage and reimbursement under Mountain State Blue Cross Blue Shield plans. Application of a medical policy to determine coverage in an individual instance is not intended and shall not be construed to supercede the professional judgment of a treating provider. In all situations, the treating provider must use his/her professional judgment to provide care he/she believes to be in the best interest of the patient, and the provider and patient remain responsible for all treatment decisions.
Mountain State Blue Cross Blue Shield (MSBCBS) retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of MSBCBS. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.
|
